This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Headache
  • /
  • Recent Advances in Pharmacotherapy for Migraine Pr...

Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Read time: 1 mins
Published:1st Mar 2018
Author: Ong JJY, Wei DY, Goadsby PJ.
Source: Drugs
Availability: Pay for access, or by subscription
Ref.:Drugs. 2018;78(4):411-437.
Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms characteristic of a migraine attack. Management of migraine is individualised and often necessitates the commencement of preventive medication. Recent advancements in the understanding of the neurobiology of migraine have begun to account for some parts of the symptomatology, which has led to the development of novel target-based therapies that may revolutionise how migraine is treated in the future. This review will explore recent advances in the understanding of migraine pathophysiology, and pharmacotherapeutic developments for migraine prevention, with particular emphasis on novel treatments targeted at the calcitonin gene-related peptide (CGRP) pathway.

Read abstract on library site

Access full article